Maraviroc
- TRADE NAMES: Celsentri (ViiV); Selzentry (ViiV)
- INDICATIONS: HIV infection
- CLASS: Antiretroviral, CCR5 co-receptor antagonist
- HALF-LIFE: 14–18 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Clarithromycin, Conivaptan, CYP3A4 inhibitors or inducers, Darunavir, Dasatinib, Deferasirox, Delavirdine, Efavirenz, Etravirine, Indinavir, Ketoconazole, Lopinavir, Nelfinavir, Oxcarbazepine, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Voriconazole
PREGNANCY CATEGORY: B
HEPATOTOXICITY
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of maraviroc in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
